2-26-04

PTO/SB/21 (01-03) Approval for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** unassigned TRANSMITTAL Filing Date February 18, 2004 **FORM** First Named Inventor Romero, Jaime Art Unit unassigned (to be used for all correspondence after initial filing) **Examiner Name** unassigned Total Number of Pages in This Submission **Attorney Docket Number** OSMO-1001 **ENCLOSURES** (check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) to Group Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to Group X Amendment / Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Change Affidavits/declaration(s) Status Letter of Correspondence Address Extension of Time Request Other Enclosure(s) (please Terminal Disclaimer identify below): **Express Abandonment Request** Request for Refund Information Disclosure Statement CD, Number of CD(s) _ **Certified Copy of Priority** Remarks Document(s) Response to Missing Parts/ Incomplete Application Substitute Specification Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Nancy Lord Johnson, Ltd. Individual Signature Date February 24, 2004

CERTIFICATE OF TRANSMISSION/MAILING						
	•	acsimile transmitted to the USPTO nrmissioner for Patents, Washington	•	tes Postal Service with sufficient postage February 24, 2004		
Typed or printed	Nancy Johnson	1	E032621	6693 W		
Signature	10/10	Hola)	Date Feb	ruary 24, 2004		

This collection of information is required by 37 CFR 15. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. Washington, DC 20231.



NANCY LORD JOHNSON, LTD

ATTORNEY AT LAW

www.nancyjohnson.net defense@mindspring.com

Licensed to Practice Law in: U.S. Patent and Trademark Office Nevada, California & Washington, DC Licensed in Medicine only in NY Practitioner of Foreign Law, B.C., Canada NANCY LORD JOHNSON, MD 361 South Frontage Road Suite 3 Pahrump, NV 89048 Tel. 775-751-3636

10/782, 245 February 24, 2004

Mail Stop Non-Fee Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

Application Number: unassigned

Inventor: Jaime Romero

Dear Sir:

Attached Please Find the Following:

Preliminary Amendment Transmittal Return Reciept Postcard Express Mail Receipt

If payment Enclosed, this Amount Is Believed to Be Correct; However, the Commissioner Is Hereby Authorized to Charge Any Deficiency or Credit Any Overpayment to Deposit Account No 50-1726.

Sincerely,

Nancy Johnson

Cc: Isaac Gilinski, Osmopharm

FEB 2 4 2004 S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

•	App	plicant(s):				
_		Romero				
5	Арг	plication No.:				
	Filed: February 18, 2004		Group Art Unit: Examiner: unassigned			
10	FOI WA	e: COMPOSITIONS AND METHODS R TIMED RELEASE OF ATER-SOLUBLE NUTRITIONAL PPLEMENTS	Examiner: unassigned			
15	Atte	orney Docket No.: OSMO-001				
		PRELIMINARY AMENDM	ENT UNDER 37 CFR 1.115			
20		Commissioner for Patents Alexandria, VA 22313-1450				
	Dear	· Sir:				
		Please amend this application as follows:				
	Ame	ndments to the Specification:				
25	1.	On page 3, line 24, paragraph [0008], after Hussein, realtes				
	2.	On page 4, line 24, paragraph [0011], after	er Odidi, <u>No.</u>			
	3.	On page 5, line 10, paragraph [0013] at	ter chondroitin as gelcaps/caplets, not pellets in			
		capsules,				
	4.	On page 6, line 23, paragraph [0016], after	er total glycosaminoglyecans			
30	5.	On page 7, line 23, paragraph [0018], after 26% bioavailaibility.				
	6.	On page 10, line 10, paragraph [0027], fo	rmulation s			
	7.	On page 12, line 22, paragraph [0030], af	ter specifically, most preferably			
	8.	On page 12, line 5, paragraph [0031], cor	ntains (strike out "s")			
	9.	On page 14, line3, paragraph [0037] after	after 4 hours about 455% to about 75%			
35	10.	On page 18, line 8, paragraph [0050]: arthichoke;				
	X.	On page 18, line 11, paragraph [0050] aft	er hops: horse chestnut.			